NTRK Fusions in a Sarcomas Series: Pathology, Molecular and Clinical Aspects

• DOI: 10.3389/pore.2022.1610423
• Publication Date: 2022-05-11T04:11:06Z
• Authors: Vasiliki Siozopoulou; Elly Marcq; Koen De Winne; Koen Norga; Gertjan Schmitz; Valerie Duwel; Philippe Delvenne; Evelien Smits; Patrick Pauwels
• Keywords: Trk receptor; Molecular Pathology

Targeting molecular alterations has been proven to be an inflecting point in tumor treatment. Especially recent years, inhibitors that target the tyrosine receptor kinase show excellent response rates and durable effects all kind of tumors harbor fusions one three neurotrophic genes ( NTRK1 , NTRK2 NTRK3 ). Today, therapeutic options most metastatic sarcomas are rather limited. Therefore, identifying which sarcoma types more likely these targetable NTRK is paramount importance. At moment, identification solely based on immunohistochemistry confirmed by techniques. However, a first attempt made describe histomorphology -fusion positive sarcomas, order pinpoint best candidates for testing. In this study, we investigate immunohistochemical expression pan-TRK 70 soft tissue bone sarcomas. The cases were further investigated with techniques presence fusion. Seven out showed positivity pan-TRK, whereas two seven presented Further analysis fused revealed some unique histological, clinical findings. goal study expand histomorphological spectrum -fused identify their fusion partners correlate parameters outcome disease. addition, evaluated pattern its correlation involved gene.